Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Recruiting

Phase 2

DWN12088Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Sponsor:

Daewoong Pharmaceutical Co. LTD.

Code:

NCT05389215

Conditions

Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

DWN12088

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD. on 2024-04-17.